Introduction

Dr. Robert Zizer and Dr. Yibin Chen discuss the series on how I manage high-risk patients following allogeneic hemipoietic cell transplantation. The background is that for the majority of patients with acute mind-related leukemia and myelodysplacic syndrome, short allohcd induces the highest remission rates or chance of cure. A fraction of patients has a particular high-risk for such complications, we call them high- risk patients. It is important to find proof of lactic and therapeutic intervention to improve the outcome of such high-risk Patients.